← Acrivon Therapeutics, Inc. (ACRV) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Acrivon Therapeutics, Inc. (ACRV)
Pharmaceutical Preparations · market cap $89M · as of 2026-07-15
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-12 (est.)
Earnings
Pipeline
2
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Acrivon Therapeutics (ACRV) is a clinical-stage pharmaceutical company with a market cap of ~$85M and 75 employees, developing ACR-368 in Phase 2 for endometrial adenocarcinoma. The company holds $97.7M in cash against a ~14-month runway, sitting at a modest net cash position relative to market cap. The key binary event is an estimated Phase 2 data readout for ACR-368 around May 2027.
The catalyst path
- 2026-11-12 (est.)Earningsimp 5/10
- 2027-05-30 (est.)Phase 2 · ACR-368imp 7/10
- 2027-08-12 (est.)Phase 2 · ACR-2316imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| ACR-2316 | Phase 2 | Specific Advanced Solid Tumors |
| ACR-368 | Phase 2 | Endometrial Adenocarcinoma |
Price & technical context
3-month
+13.5%
6-month
+32.9%
12-month
+11.6%
52-wk range
$1.29–$3.01
vs 50-day MA
+5.0%
vs 200-day MA
+11.2%
Realized vol
90.8%
Max drawdown
-88.9%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for ACRV (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.